Cargando…
Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases
OBJECTIVE: To study the efficacy and safety of arbidol hydrochloride tablets as a treatment for influenza-like diseases. METHODS: In this multicenter, randomized, controlled, open label study, a total of 412 influenza-like cases were collected from 14 hospitals in seven regions of Hebei Province fro...
Autores principales: | Bai, Xinfeng, Xi, Suya, Chen, Guiyan, Fan, Xiaoying, Wang, Kaiwei, Li, Yong, Zhao, Yang, Wang, Weizhan, Tian, Yingping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483848/ https://www.ncbi.nlm.nih.gov/pubmed/37674112 http://dx.doi.org/10.1186/s12879-023-08570-9 |
Ejemplares similares
-
A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022) -
Improving the Solubilization and Bioavailability of Arbidol Hydrochloride by the Preparation of Binary and Ternary β-Cyclodextrin Complexes with Poloxamer 188
por: Anwer, Md. Khalid, et al.
Publicado: (2021) -
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
por: Li, Ting, et al.
Publicado: (2020) -
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
por: Chen, Chang, et al.
Publicado: (2021) -
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
por: Wang, Xi, et al.
Publicado: (2020)